Melissa Alsina, M.D.
H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Melissa Alsina, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03411031 · Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideH. Lee Moffitt Cancer Center and Research Institute · terminated · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT02802163 · Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatH. Lee Moffitt Cancer Center and Research Institute · withdrawn · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT00750815 · Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)H. Lee Moffitt Cancer Center and Research Institute · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT00361088 · A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaH. Lee Moffitt Cancer Center and Research Institute · terminated · Multiple Myeloma · principal investigator
- Ph2NCT00005624 · CI-994 in Treating Patients With Advanced MyelomaH. Lee Moffitt Cancer Center and Research Institute · completed · Multiple Myeloma · principal investigator
- Ph2NCT00012350 · Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple MyelomaH. Lee Moffitt Cancer Center and Research Institute · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.